CCM
BXRX

Corsair Capital Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Corsair Capital Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-65
Closed -$92K – 114
2020
Q4 		$92K Sell
65
-244
-79% -$499K 0.02% 71
2020
Q3 		$1.2M Sell
309
-313
-50% -$1.42M 0.43% 25
2020
Q2 		$3.61M Sell
622
-7
-1% -$33.6K 1.48% 17
2020
Q1 		$2.18M Buy
629
+42
+7% +$397K 1.04% 24
2019
Q4 		$5.68M Buy
+587
New +$5.01M 1.7% 22

Other funds holding BXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Corsair Capital Management's BXRX Position: Q1 2021 in Review

Corsair Capital Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q1 2021, closing a stake of 65 shares — an estimated $92K sold.

Corsair Capital Management first reported a position in BXRX in Q4 2019 and held it in 5 quarters. The position peaked at $5.68M in Q4 2019. 31 funds tracked by Wall St. Rank hold BXRX as of Q1 2021.

  • Corsair Capital Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Corsair Capital Management sold 65 Baudax Bio, Inc. Common Stock shares in Q1 2021, an estimated $92K.
  • Corsair Capital Management first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Corsair Capital Management's Baudax Bio, Inc. Common Stock position peaked at $5.68M in Q4 2019.
  • 31 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q1 2021.

Based on Corsair Capital Management's 13F filing for Q1 2021, filed 14 May 2021.